Drug Profile
Proliposomal paclitaxel - LIPAC Oncology
Alternative Names: LEIPC-1007; LEIPC-1008; LEITP-1009; LiPax; PLIP; TBC-1002; TSD 001; TSD 005; UTUC 1005Latest Information Update: 16 Mar 2023
Price :
$50
*
At a glance
- Originator TesoRx
- Developer LIPAC Oncology; TesoRx
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Bladder cancer
- Preclinical Mesothelioma; Ovarian cancer; Peritoneal cancer; Pleural effusion; Urogenital cancer
Most Recent Events
- 16 Mar 2023 Preclinical development in Urogenital-cancer is ongoing in USA (Intraluminal) (TesoRx pipeline, March 2023)
- 16 Mar 2023 Phase-II clinical trials in Bladder cancer in USA (Intravesicular) prior to March 2023 (TesoRx pipeline, March 2023)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Urogenital-cancer in USA (Intraluminal)